Company intelligence / Profile preview

Dolphin I

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Dolphin I was a clinical-stage biopharmaceutical company focused on developing next-generation metabolic therapies. The company primarily worked on oral small molecule agonists targeting the GLP-1 and glucagon receptors for the treatment of obesity and related metabolic disorders. Its lead programs aimed to provide more accessible and convenient alternatives to injectable peptide-based incretin therapies. In 2024, the company was acquired by a major pharmaceutical firm to bolster its metabolic disease pipeline.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Dolphin I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dolphin I.

Explore the full profile